Company details, activities, locations, contacts, financials and reviews for Vigene Biosciences.
Main company details for Vigene Biosciences.
Vigene Biosciences, Inc. was founded in 2012 to provide services and products to support the rapidly growing field of gene therapy. At the time, adenovirus was the primary viral vector used, so Vigene developed cloning technologies to generate the largest collection of full-length human open reading frames packaged in adenovirus. Over the next few years, different viral vectors became more widely used for research, so Vigene expanded its viral packaging and cloning services to include the major viral vectors being used for gene delivery (AAV, adenovirus, lentivirus, and retrovirus). Vigene also diversified its product portfolio to include control viruses, shRNA clones, biosensors, and Parkinson’s disease tools. In 2016, Vigene acquired Omnia Biologics with its 15+ years of clinical manufacturing experience in response to the growing need for high titer, clinical-grade viral vectors as gene therapy candidates progressed to clinical trials. Since then, Vigene has continued to serve both research and clinical communities and has been recognized with national awards. Currently Vigene operates a 110,00 sq ft state-of-the-art facility with over 15 GMP cleanroom suites.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Vigene Biosciences on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.